|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/7048 | (2006.01) |
| A61K 31/7048 | (2013.01) | ||
| A61K 31/55 | (2006.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61P 13/12 | (2018.01) | ||
| A61P 13/12 | (2006.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 43/00 | (2006.01) | ||
| A61K 9/2018 | (2013.01) | ||
| A61K 9/20 | (2006.01) | ||
| A61K 9/2054 | (2013.01) |
| (11) | Number of the document | 3826642 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19742218.1 |
| Date of filing the European patent application | 2019-07-23 | |
| (97) | Date of publication of the European application | 2021-06-02 |
| (45) | Date of publication and mention of the grant of the patent | 2025-05-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2019/069815 |
| Date | 2019-07-23 |
| (87) | Number | WO 2020/020896 |
| Date | 2020-01-30 |
| (30) | Number | Date | Country code |
| 18185598 | 2018-07-25 | EP |
| (72) |
VON EYNATTEN, Maximilian , DE
GROSS, Oliver , DE
HAUSKE, Sibylle, Jenny , DE
|
| (73) |
Boehringer Ingelheim International GmbH ,
Binger Strasse 173, 55216 Ingelheim am Rhein,
DE
|
| (54) | EMPAGLIFLOZIN FOR USE IN TREATING ALPORT SYNDROME |
| EMPAGLIFLOZIN FOR USE IN TREATING ALPORT SYNDROME |